<DOC>
	<DOCNO>NCT02531035</DOCNO>
	<brief_summary>This Phase 3 study design demonstrate net benefit sotagliflozin versus placebo patient T1D .</brief_summary>
	<brief_title>A Phase 3 Study Evaluate Safety Sotagliflozin Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Patient give write informed consent participate study accordance local regulation Adult patient 18 year old diagnosis T1DM make least 1 year prior informed consent Patients treat insulin insulin analog Willing able perform selfmonitoring blood glucose ( SMBG ) complete study diary require per protocol At Screening Visit , A1C must 7.0 % 11.0 % Females childbearing potential must use adequate method contraception negative pregnancy test Use antidiabetic agent insulin insulin analog time screen Use sodiumglucose cotransporter ( SGLT ) inhibitor within 8 week prior screen Chronic systemic corticosteroid use Type 2 diabetes mellitus ( T2DM ) , severely uncontrolled T1D determine Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>